BeneVir is developing a therapeutic platform that has the potential to cure cancer in patients with advanced tumors
Location: United States, Maryland, Rockville
Employees: 11-50
Total raised: $3M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | BioHealth ... | biohealthi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.02.2016 | - | $3M | - |
Mentions in press and media 6
| Date | Title | Description |
| 02.05.2018 | Term Sheet — Wednesday, May 2 | 5 Qs WITH A DEALMAKER In February, Reddit co-founder Alexis Ohanian said he would step down from his daily role at the company to return to investing. Paid Content You can't secure what you can't see From ExtraHop “I still use Reddit to dis... |
| 16.02.2016 | Oncolytic immunotherapy startup BeneVir gets $3M | The company, launched in 2011, gets its core technology from New York University. BeneVir claims its platform, called T-Stealth, “overcomes a major barrier to the clinical success of oncolytic viruses” It’s referring to the immune system, w... |
| 26.11.2014 | Building viruses that kill cancer cells: BeneVir gets $2M, waiting on $10M more | The money will go toward the first proof-of-concept clinical studies, expand the startup’s pipeline and “establish partnerships to test promising combination therapies in a diverse set of metastatic solid tumors.” BeneVir says its platform ... |
| 19.11.2014 | BeneVir Biopharm Receives Series A Investment from Pansend | BeneVir Biopharm, Inc., a Rockville, MD-based biotechnology company developing a pipeline of cancer immunotherapies, closed a Series A investment round with Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. (OTCQB: HCH... |
| - | Building viruses that kill cancer cells: BeneVir gets $2M, waiting on $10M more | Immunotherapy is at the forefront of cancer care; however, most cancers evolve the ability to dodge the body’s defenses. Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells – those that... |
| - | Oncolytic immunotherapy startup BeneVir gets $3M | Maryland cancer vaccine upstart BeneVir is taking a two-pronged approach to immuno-oncology – it’s developing viruses that can rid the body of tumor cells that cause cancer and cause it to recur. It just brought in $3 million of a proposed ... |